{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-23-000002","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.425280+00:00","generated_at":"2026-06-20T19:02:34.826099+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"QuidelOrtho Q4 2022 preliminary revenue $853-868M; non-COVID rev up 18% proforma constant currency","bullets":["Preliminary Q4 total revenue $853M-$868M; COVID $124M-$134M; non-COVID $729M-$734M.","Non-COVID product revenue grew 485% GAAP, 18% proforma constant currency; driven by strong respiratory season.","Full year 2022 total revenue $4,038M-$4,053M; non-COVID $2,597M-$2,602M (11% proforma constant currency growth).","CEO Doug Bryant cited growth across Molecular Diagnostics, Transfusion Medicine, and Point of Care units.","Full earnings results and conference call scheduled for February 15, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-23-000002","json":"https://secwatch.observer/filing/0001906324-23-000002.json","markdown":"https://secwatch.observer/filing/0001906324-23-000002.md","text":"https://secwatch.observer/filing/0001906324-23-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000002/0001906324-23-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000002/qdel-20230106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:02:34.826099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14df3daa03f95ea40ad0787e16ae0504e88d3d81","claim":"QuidelOrtho Corp reported the fourth quarter ended January 1, 2023 results: revenue $853 million to $868 million.","evidence_excerpt":"The Company expects total revenues in the fourth quarter of 2022 to be in the range of $853 million to $868 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000002/0001906324-23-000002-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended January 1, 2023"},{"label":"Revenue","value":"$853 million to $868 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"246cd454711639785c1155c391ea4b2f75eee966","claim":"QuidelOrtho Corp reported the full year ended January 1, 2023 results: revenue $4,038 million to $4,053 million.","evidence_excerpt":"The Company expects total revenues in the full year of 2022 to be in the range of $4,038 million to $4,053 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000002/0001906324-23-000002-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended January 1, 2023"},{"label":"Revenue","value":"$4,038 million to $4,053 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}